Advancements in Stimuli-Responsive Nanocarriers for Targeted Intracellular Delivery of Smart Chemotherapeutics: Comparative Analysis of Drug Delivery Efficiency, Cytotoxicity, and Safety Across Stimuli Types and Cancer Cell Lines

The pharmacotherapeutic potential of the drug not only correlates with the pharmacological properties, but the efficacy mainly depends upon the efficiency of the delivery of the drug into the desired organ concentrations. To begin with, the better, most desirable mechanism of drug delivery that must deliver the desired concentrations of the drug into the organ, not into the rest of the tissues, the desired amount for the needed time.

Yet, it has a definite limitation regarding its non-specific distribution within the body, clearance of the drug within the blood, non-availability of the drug in low concentrations within the body, and the toxicity of the drug, which develops when a definite limit of the concentration of the compound is present. In the context of chemotherapy of cancer patients, a drug of toxic nature attacks both cancer and non-cancer cells due to its inherent higher toxicity and lower patient compliance.^[1,5,7]

So, in order to avoid all these problems, the major focus in the recent studies is given to the design of advanced drug carriers or drug delivery systems, where drugs could release efficiently in a precise manner. Of all the drug carriers, the drug delivery system is found to hold promise in terms of access in the recent past to release the drug in relation to certain stimuli. Usually, the drug delivery system would not show changes in terms of molecular changes or changes in drug structures unless it is specifically exposed to certain stimuli. There would not be any molecular changes in terms of changes in molecular structures unless it is specifically released in the drug delivery system. Such precise.^[6,8,12]

The fast rate at which developmental progress is being achieved in the field of nanotechnology is among the major causes behind the invention of new forms in drug delivery. These nanocarriers, which come in a variety of dimensions that fall in the nanometers scale up to the number of hundred nanometers scale, exhibited several advantages, apart from the long circulation period of the drug in the system, the large surface area, the large drug quantity it is able to interact with, in addition to the fact that the drug is able to interact with the functional parts of the micro-environment around the location of the diseases.^[11,14,18]

Certain tissue structures, particularly tumors, have numerous characteristics of their microenvironment, which have fewer or no incidence in normal tissue. Some of these characteristics of tumor microenvironments, which serve as stimuli or stimulons, include acidic pH of an external nature, high concentration of reducing agents like glutathione, overexpression of enzymes, and production of reactive species of oxygen. As stimulons or stimuli, it is believed that some alteration in stimulon-sensitive carriers, particularly concerning certain properties that affect the micro-environment or pathology of tissue, leads to a controlled release of drugs through destruction of polymers, breaking.^[16,19,22]

However, owing to the integration of responsiveness that the stimuli expose, the result has been the introduction of many delivery platforms that have been incorporated within stimuli-responsive nanocarriers, such as polymeric nanoparticles, polymeric micelles, liposomes, lipid nanoparticles, inorganic nanoparticles, hybrid nanoparticles, biomimetic nanoparticles, nanodrugs without carriers, among many. Many delivery vehicles, regardless, have manifested their potential, especially due to their propensity to highly enhance efficacy within many diseases, such as cancer, inflammatory diseases, gene therapy, and many more. However, challenges still exist, mainly regarding the longevity or scaling up.^[21,24,29]

Of course, it should be noted that so much emphasis and importance have been placed within this review article in terms of the state of the art of stimuli response nanocarriers, meaning the perspectives of the advancements within stimuli responsive nanocarriers in terms of basic ideas, the different stimuli responses, etc., basically in terms of nanocarriers, as well as the outlook of the perspectives in terms of the state of the art of stimuli responses nanocarriers that could potentially be formed through the advancements within the perspectives of the potentials of stimuli responses within the field of drug delivery. ^[26,31,34]

 

 

Fig 2. Classification of stimuli-responsive nanocarriers based on endogenous and exogenous triggers.

6. Lipid-Based Nanocarriers for Stimuli-Responsive Drug

6.1 Overview of Lipid-Based Nanoparticle

 Lipid nanoparticles have shown their application as an established drug delivery system that proves to have impressive bio-compatibility and outstanding bio-degradability. Note that one of the most significant advantages of the composition or importance of using this compound, or similar compounds, to carry out nanoparticle composition is that there is an abundance of such materials, making it a bit comparable to biological membrane structures in such a way that it should be prevented from acquiring toxic and antigenic properties. Moreover, because of its non-toxic nature and due to the easiness of its composition or production, such nanocarriers have already transferred from a lab into hospitals.^[3,14]

Moreover, in the class of "Drug delivery systems responding to external stimuli," it is possible that "Lipid nanoparticle systems" can also be engineered to make it more 'flexible in terms of incorporation of responsive elements in their lip bilayers and/or cores and in responding to external stimuli in order to achieve controlled release, which, in turn, will enhance their therapeutic index and minimize systemic toxicities."^[8,31]

6.2 Liposomes

Liposomes have spherical structure and are composed of single or double layers of phospholipids encapsulating an aqueous core. Liposomes have amphiphilic properties, which aid in encapsulating the hydrophilic and hydrophobic drug in the aqueous core and lipid bilayers, respectively. Liposomes have undergone intensive research and have already been in practice in the field of drug-delivery system.^[6,18]

Stimuli-responsive liposomes are prepared by the use of pH-sensitive, thermo-sensitive, or enzyme-cleavable lipids. These liposomes are stable under physiological conditions but decompose upon exposure to pathological stimuli such as low pH or increased temperatures. Thermo-sensitive liposomes have indeed shown immense potential in cancer therapy when used in conjunction with local hyperthermia. There is controlled drug delivery as the drugs are delivered right at the tumor site.^[11,39]

6.3 Solid Lipid Nanparticle (SLN_S)

These submicron drug carriers are manufactured using solid lipid compounds as well as the surfactant group. Like the liposome drug carrier, the drug carriers will also contain solid lipid in the core. These drug carriers produced lipospheres that provide drugs with protection from chemical degradation. The feature of controlled drug release is widely recognized in drug lipospheres; thus, this process is used to deliver drugs that are lipid-soluble in nature.

Stimuli-responsive SLNs can be formulated by incorporating stimuli-sensitive lipids or additives that can induce a drug release system to react against a certain external stimulus. Temperature changes and reduction in pH can induce a drug release system to react by altering lipids in order to control a drug release system. However, low drug content capacity and drug ejection upon lipid crystal development are considered to be the disadvantages of SLNs.^[9,22]

6.4 Nanostructured Lipid Carriers

It shall, in fact, be observed that in consideration of the above-mentioned aspects, it may be stated that nanostructured lipid carries represent an advanced form of lipid nanoparticles, which has been developed in an effort to transcend the disadvantages of conventional SLN, which were discussed in the above paragraphs. These comprise the composition of the mixture of solid lipid compounds, like the already explained, but in the form of liquids, concocted in the same proportion to form an imperfect matrix of the lipid part in the aim to attain the superior drug loading capacity in the decrease of drug expulsion.^[12]

While in the case of stimuli-sensitive NLCs, there is an ability that exists due to their nature, which may permit the release of drugs depending on certain conditions that can be explained in a pathophysiological way.^[36]

Thus, the major advantage of the system is the enhanced stability, capacity, and the drug profile, whereby the drug carrier and delivery system’s potential is enhanced and most promising, especially in the long term.

Currently, the viability in the utilization of NLCs is demonstrated in the targeting of anticancer drugs, anti-inflammatory drugs, and nucleic acid drug delivery.^[20]

7. Inorganic and Hybrid Nanocarriers for Stimuli-Responsive Drug Delivery

7.1 Introduction to Inorganic and Hybrid Nanocarriers

 Inorganic nanocarriers form one category of the types of nanocarriers. They vary from one another according to their own specific physicochemical features. Equally so, the optical features. On a broader level, they can be made from materials ranging from silica, gold, iron oxide, to even other metal structures. However, the vast majority of them have largely been studied due to their intrastructural stability, tunability, and multi-functionality. In relation to their role in responsive drug delivery, inorganic nanocarriers have proven themselves to be incredibly functional due to their responsiveness to stimuli, be it light, magnetic, or even redox.

Hybridized nanovehicles have an inorganic core and an organic or polymeric coating, which might, in theory, integrate the best properties of each class of materials in question. This hybrid material provides greater bio-compatibility, increases the cargo delivery potential of the system, and provides an opportunity to manipulate exactly what sort of release results. Specifically, hybridized cores using stimuli-sensitive polymeric or 'gatekeeper' molecules provide immense possibilities in controlling release and have greater material rigidity.^[4,16,28]

7.2 Mesoporous Silica Nanoparticles

Among all the inorganic nanocarriers, mesoporous silica nanoparticles have been one of the most studied nanocarriers owing to their very high surface area, tunable pore size, and very good chemical stability. These nanoparticles are similar to nanocontainers, being able to host a large amount of therapeutic agents inside their meso-structured porous framework.^[6,19]

Generally, stimulus-responsive mesoporous silica systems are designed with the aid of "gatekeeper" strategies. In physiological conditions, the blocking of pore openings by stimulus-sensitive molecules inhibits the premature leakage of drugs. These gatekeepers are destroyed under the action of specific stimuli-low pH, high glutathione levels, or enzyme activities-allowing rapid drug release. That is the mechanism of controlled release that provides high suitability of mesoporous silica nanoparticles for targeted cancer therapy.^[14,26]

7.3 Gold Nanoparticle

Currently, the interest in drug delivery is in gold nanoparticles in view of their good bio-compatibility, surface capability, and good optical properties. As far as the capability of gold nanoparticles is concerned, it is extremely large; this is in the sense that rays are converted into heat.

The type of drugs in the stimulus-sensitive systems may either bond with the gold NPs through a volatile bond, or adsorb with the NPs of gold. The impact of laser triggers leads to destruction of the cells, killing the cancerous cells, through the photothermal action. The two methods for improving the type of drug efficacy, as well as cell specificity, are embedded in the gold nanoparticle .^[8,31,34]

7.4 Magnetic Nancarriers

Overall, the composition of most types of magnetic nanocarriers consists of iron oxide nanoparticles that exhibit sensitivity to a specific magnetic field. Nonetheless, one of the unique benefits of the use of nanoparticles lies in the phenomenon of the attraction to the diseased site caused by the static magnetic field—the target.

Also, considering an alternating magnetic field, drug release can be induced even after magnetic hyperthermia has taken place, where heat is generated inside the tissue, and such a possibility exists when thermo-sensitive coatings/polymer layers are used. In addition, magnetic nanocarriers can be used as contrast agents and then used in conjunction with magnetic resonance images, which is diagnostic and therapeutic. Even with these positive attributes of magnetic nanocarriers, optimal testing needs to be done regarding the problems relating to magnetic strength and safety.^[18,30]

7.5 Hybrid Nanocarriers

These hybrid nanocarriers involve the incorporation of inorganic components onto the surface of polymers or lipid structures to enhance their biocompatibility. It can be noted that the surface of the nanoparticles formed from the organic material may be responsive to stimuli for controlled release of the drug. That would mean the nanoparticles could be the active components of the system.

Such hybrid systems can dryingly respond to any of these stimuli, hence serving the application of drug delivery systems using combined pH sensitivity, redox sensitivity, photostimulants, and magnetic stimuli sensitivity. Consequential hybrids are thus capable of bringing about the synergistic effect necessary for precision medicine applications. However, the complexity of the preparation can be a hindrance to application with hybrid nanoparticles.^[11,19,31]

8. Biomimetic Nanocarriers & Carrier Free System

8.1 Biomimetic and Carrier-Free Systems Overview

The advancements that nanomedicine is able to achieve in the field have seen the creation of biomimetic nanocarriers/drug carriers that require the process of self-assembly if the challenges facing the synthesized carriers will be overcome. These drug carriers utilize self-assembly techniques in the process that entails the utilization or the process of self-assembly to enable the carriers used to evade the process of immunity. The process essentially imitates natural entities or makes the process using synthesized carriers irrelevant.^[5,16]

Biomimetic Nanocarriers involve the application of natural biological membranes/biological vesicles, which are of cellular origin. Carrier-Free Nanodrugs involve the application of only drugs/prodrugs. The application of less number of synthetic agents is incorporated in two nanoscales of drug forms. These are very effective, as the chances of the occurrence of even a small level of chronic toxicity are less.^[5,17,33]

8.2 Cell Membrane Coated Nanocarriers

Cell membrane-coated nanocarriers represent the most biomimetic system, which include synthetic nanoparticles coated with the cell membrane. Cell membranes derived from red cells, cancer cells, immunocytes, and platelets are mainly used. Since the nanoparticles are coated with the cell membrane, the capability to create the biinterface, evade immunologic recognition, have the capacity to live long, and bind the nanoparticles are achieved.^[9]

For instance, if we want to make a nanodevice that can sense a certain stimuluses, the NP may be able to sense it either in terms of pH or redox; thereafter, the membrane becomes a cloaking system. Finally, the nanodevice reaches the specific site of the body where the disease manifests. Thereafter, it senses the stimuluses—the core part of the nanoproduct changes accordingly, leading to the release of the drugs prescribed. This system shows the specificity of the system.^[16,34]

8.3 Carrier-Free Nanodrugs

The particular drug delivery methods, though nanoscale-based with no carrier of their own, make use of a minimalist drug delivery approach where the drug molecule is chemically modified such that it has the ability for self-assembly into nanoparticles.

The specific kind of drug delivery system, however, can be designed using drug conjugates or drug prodrug agents, which exhibit amphiphilic characteristics, through covalent cross-links controlled using specific stimuli.^[7,34]

Once the drug is assembled, it is ready to be used as a carrier and as a drug itself.

This means that carrier-free nanodrugs have an ability to react to certain stimuli, and hence, it will take that long before it reaches the environment surrounding the cell where it will react accordingly to certain stimuli. Therefore, it was evident that there was an use of using carrier-free nanodrugs in giving treatment to cancer, considering the level of its capability and level of toxicity.^[14]

9. Evidence - Responsive Nanocarriers in Therapy

9.1 Application in Cancer Therapy

Considering the complex and disparate nature of tumor environments, arguably the most extensively explored cancer treatment is tumor-targeted drug release within the context of drug carrier nanotechnology. With regard to the application of the ordinary chemotherapeutic drug, the disadvantages of using drug carrier nanotechnology lie in the lack of specificity of the drug distribution, its inherent highly toxic nature, and drug resistance; such disadvantages offset the desirable drug treatment regimens administered to the human body. In the context of drug carrier nanotechnology, the inherent spontaneous production of a multitude of tumor-related specific signals directly associated with tumor production is advantageous in tumor drug release and includes a low pH level, highly enriched enzymatic processes, a reduction/oxidation reaction disproportionate balance, and hypoperfusion.^[6,18]

This mainly has to do with the targeted delivery, which addresses the issue explained above. The nanocarriers, over time, remain stable in the blood, accumulating in the cancer site semi-persistently because the permeability increases, making it easier to accumulate the drugs in the site. Once this has occurred, the structural changes in the nanocarriers, triggered by the events in the cancer cells, ensure the drugs are delivered intracellularly in no time. This kind of delivery method ensures the drug concentration in the cancer cells is maximized, allowing minimal damage to the normal cells in the body.Besides that, the externally triggered systems ensure the best possible results in cancer treatment.^[12,27]

9.2 Application in Inflammatory and Autoimmune Diseases

also includes inflammation, autoimmune diseases, activation of the immune system, overexpression of enzymes, change of pH, oxidative stress, etc., within the inflammatory area. The properties of inflammation, as stated above, provide better sources of stimuli for drug delivery systems. Conventional anti-inflammatory drugs have normally shown dose dependency in the body to induce toxicity in the body, as well as poor patient compliance.^[5]

The fact that the stimuli-responsive nano-carriers are able to effectively carry out the targeted delivery of the drugs involved in the reduction of the inflammatory processes in the body implies that it is in conformity with the assertion that the cell is responsive to some specific stimuli, including the activities of some specific enzymes and/or the production of reactive oxygen species in the process in which diseases occur. It should be appreciated that the targeted drug delivery, as opposed to the conventional drug delivery system, would result in an enhanced level of effectiveness in the medicinal drugs involved in the reduction of the effects, including the adverse effects, encountered in the process. The biomimetic nano-carriers, in consideration of the cell membrane that surrounds the nano-particles, imply the effectiveness of the nano-carriers in the process of targeting the cells involved in the stimulatory processes, in the sense that the nano-carriers would evade the immune system.^[17,29,31]

9.3 Application in Gene Therapy

Furthermore, the major problem encountered by gene therapy is also experienced within the release of theDNA/RNA, and it is the enzymaticdegradation of bio molecules as well as the phenomenon of cellular uptake and the entrapment of the carriers by the endosomes.

Investigation of the role of exogenous factors such as the effect of ultrasound, magnetic waves, etc., leading to the permeability of the blood as well as the brain, and thus facilitating the drugs in diffusing in the specific area of the brain in the process of inducing the permeability of the BBB, is also under intensive investigation. On the contrary, the role of this system in connection with the reaction of the endogenous stimulus concerning the activities of the redox reaction in the brain tissue is vast in the management of neurodegenerative diseases.^[7,24,38]

9.4 Application in Neurological Disorders

The issue of drug delivery to the central nervous system has actually been a major concern due to the existence of the blood-brain barrier, which hinders the passage of most of the drugs to the central nervous system. The use of nanocarriers is significant since they respond to the stimulus.^[16]

Exogenous stimuli such as ultrasound waves and magnetic waves have been researched for the temporary increase in the permeability of the blood-brain barrier and the induction of drug diffusion in the particular areas of the brain. Conversely, the systems associated with the reaction of the endogenous stimulus to the redox and enzymatic activities in the brain tissues offer vast possibilities in the management of neurodegenerative diseases.^[30]

10. Challenges, Clinical Translation, and Regulatory Issues

10.1 Challenges in Manufacturing and Scale

Even though there has been copious amounts of research into formulating nanoparticles, as has been discussed in this particular paper, with regards to the production of such a large quantity of the drug, it has been identified as one of the biggest problems in terms of making use of it in a particular condition. While it has been observed that there has been remarkable success in terms of formulating drug carriers, a particular methodology has been observed in terms of producing this particular drug, as well as its reaction to a particular stimulus.^{[14 29]}

Another factor which is to be taken into consideration is the rates of clearance and biodistribution. It is recognized as well as absorbed in the mononuclear cell related to the phagocytic cell type. In view of this, the process of passive targeting is applied, where the nano-particles accumulate in the target cells, including the liver as well as the spleen. Additionally, the chronic dosing of non-degradable substances is another factor, to be considered while the issue of toxicity is concerned.^[12,44,48]

10.2 Stability, Biodistribution,

“Stable and safe performance of the formula over a prolonged period of time is one of the principal requirements for the acceptance of nanoparamedical formulae. A successful nanoparamedics system should demonstrate stable performance for the duration of the formula storage and circulation phase in the blood and prevent premature drug release.” Nevertheless, nanoparamedics face problems such as nanoparamedic aggregation and degradation and unwanted activation of the stimuli-sensitive nanoparamedics.^[8,21]

The biodistribution and clearance rate are also important parameters in determining the safety criteria. The nanocarriers are easily recognized by the mononuclear phagocytic system. This leads to the passive targeting mechanism where the nanoparticles are primarily accumulated in desired organs like the liver and spleen. The long-term presence of non-degradable foreign materials inside the body is also another factor of concern in relation to chronic

toxicities.^[12,16,30]

10.3. Difficulties in translation

Nevertheless, it may be pointed out that the approval of stimuli-responsive nanocarriers is a procedure unto itself, considering the multifaceted aspects involved. This, in a manner of speaking, may be regarded as differing from the normal drug molecules as it depends on the size.Various information is sought by the authority on issues of physicochemical properties, reproducibility, toxicity tests, and the principle of therapeutic advantage. In the absence of universal and accepted standard regulations regarding nanomedicines, the process of evaluation would increase both the cost and time associated. This is in view of the fact that no nanocarriers-based therapy has been able to progress beyond the level of early clinical trials.^[9,18,33]

10.4 Economic and Practical Considerations

Along with the scientific and legal issues, cost-effectiveness/economic viability also plays an equally important role in the acceptability of nanocarriers as a possible candidate within the realm of traditional clinical practice. This is due to the fact that nanocarriers are usually prohibitively expensive for the process of preparation.

In the systems that require external stimulation, there will be a need for other infrastructural needs such as light, magnetic fields, and ultrasonic systems. This shows that there should be a good balance in terms of technology development and cost-effectiveness in the case of nanocarriers in the new system.^[14,29,50]

11. Future Perspectives and Conclusion

11.1 Outlook

The trend, as envisaged, in relation to stimuli–responsive nanocarriers involves betterment and viable routes for developmental phases towards even more advanced stimuli–responsive nanodevices. Even as the starting point of this research was focused within the realm of developing stimuli–responsive nanotechnology through various single stimuli, the trend defined today speaks of better accuracy and management capabilities in relation to what was evident in 'single stimuli responsive systems,' particularly with respects to varied sequential responses associated within the realms of stimuli types as pH Values, Redox Potential, Enzymes, and Energy Sources.^[6,21,38]

Yet another emerging route is the use of a combination of stimuli-responsive nanocarriers and precision medicine. There has also been a development in the genetic profiling of diseases and the respective disease-related biomarkers associated with patients in the last two decades. Now, however, it is possible to design nanocarriers using patient-specific pathophysiological patient data. Perhaps this is what it is going to take to end heterogeneity once and for all.^[12,27]

Another field that also shows some promise in terms of enhanced and fast progress is the incorporation of artificial intelligence/machine learning strategies in nanomedicines. The computer algorithms show promising chances of contributing to the speeding up of some of the processes, particularly in terms of material procurement, optimization of the structure of nanoparticles of the materials, computer modeling of drug delivery, as well as toxicology, processes that have proved to be cumbersome, thus acting as barriers in the innovation transfer.

Apart from this, combined therapy by means of the assistance of nanocarriers, which register a positive response towards external elements, is possibly expected to witness a number of applications within the imminent years. Simultaneous treatment by means of the assistance of a nanocarrier for chemotherapeutic agents/photothermal agents along with immunomodulatory agents is possibly expected to ensure a synergistic effect of both agents while reducing toxicity.^[18,34]

CONCLUSION

Stimuli Responsive nano-Carrier, a revolutionary concept in the field of drug delivery system technology, adds the value of site-specific targeted delivery of medicine with the help of a control mechanism. This property of these carriers is what makes them superior to existing DDS as they take advantage of the difference present in pathological tissues for an enhanced targeted action.It has been observed that different types of nanocarriers, namely, polymeric, lipidoid, inorganic, and biomimetic, were developed to respond to a variety of stimuli. These types of nanocarriers were explored, thus depicted their huge potential in the treatment of a broad range of diseases, including cancer, inflammatory diseases, gene therapy, and neuroscientist diseases. It has to be highlighted here that though these types of nanocarriers were successful in the application in different types of diseases, the cost factor, especially in the longer safety assessment, has been of prime interest.

The way forward for this field greatly depends upon simplicity relating to nanocarriers, scalability, standard evaluation procedure, standards, or collaboration involving various experts. The field, with innovative thoughts, integration, or collaboration involving various/new technologies, has huge possibilities relating to the revolution of exact medication involving wise nanocarriers.

REFERENCES

1. Al-Thani AN, Jan AG, Hajialthakar Z, Awad A, Abbas M. Next-generation nanoparticles for cancer and autoimmune therapy. Biochem Pharmacol. 2025;242:117298.
2. Zeinali R, Zaeifi D, Zolfaghari-Moghaddam SY, Paul MK, Biazar E. Current advances in nanocarriers for cancer therapy. Int J Nanomedicine. 2025;20:12243–12258.
3. Sun L, Liu H, Ye Y, Miao YB, Cai L. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023;8:418.
4. Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers. Expert Opin Drug Deliv. 2021;18(2):205–227.
5. Zhao X, Bai J, Yang W. Stimuli-responsive nanocarriers for cancer therapy. Cancer Biol Med. 2021;18(2):319–335.
6. Zandieh MA, Farahani MH, Daryab M, Motahari A, Gholami S, Salmani F, et al. Stimuli-responsive nanoarchitectures for phytochemical delivery. Biomed Pharmacother. 2023;166:115283.
7. Luo S, Lv Z, Yang Q, Chang R, Wu J. Stimulus-responsive polymer nanocarriers. Pharmaceutics. 2023;15(7):1928.
8. Kaushik N, Borkar SB, Nandanwar SK, Panda PK, Choi EH, Kaushik NK. Nanocarrier cancer therapeutics. J Nanobiotechnol. 2022;20:152.
9. Murugan B, Sagadevan S, Fatimah I, Oh WC, Hossain MAM, Johan MR. Smart stimuli-responsive nanocarriers. Nanotechnol Rev. 2021;10:933–953.
10. Wang T, Wu C, Hu Y, Zhang Y, Ma J. Stimuli-responsive nanocarrier delivery systems for Pt-based antitumor complexes. RSC Adv. 2023;13:16488.
11. Chang D, Ma Y, Xu X, Xie J, Ju S. Stimuli-responsive polymeric nanoplatforms. Front Bioeng Biotechnol. 2021;9:707319.
12. Thomas RG, Surendran SP, Jeong YY. Tumor microenvironment-responsive nanoparticles. Front Mol Biosci. 2020;7:610533.
13. Mi P. Stimuli-responsive nanocarriers for drug delivery and theranostics. Theranostics. 2020;10:4557–4588.
14. Sun Y, Davis E. Nanoplatforms for targeted stimuli-responsive drug delivery. Nanomaterials. 2021;11:746.
15. Abdo GG, Zagho MM, Khalil A. Stimuli-responsive drug release using mesoporous silica nanoparticles. Emergent Mater. 2020;3:407–425.
16. Zhang Q, Kuang G, Li W, Wang J, Ren H, Zhao Y. Stimuli-responsive gene delivery nanocarriers. Nano-Micro Lett. 2023;15:44.
17. Meng X, Shen Y, Zhao H, Lu X, Wang Z, Zhao Y. Redox-manipulating nanocarriers. J Nanobiotechnol. 2024;22:587.
18. Parra-Nieto J, Aguirre de Carcer I, García del Cid MA, Jimenez-Falcao S, González-Larre J, Baeza A. Stimuli-responsive nanocarriers in immunotherapy. Adv Mater Interfaces. 2024;11(30).
19. Graham W, Torbett-Dougherty M, Islam A, Soleimani S, Bruce-Tagoe TA, Johnson JA. Magnetic nanoparticles for cancer therapy. Nanomaterials. 2025;15(4):285.
20. Kar NP, Lin J, HassankhaniRad A, Li W, Aboushanab AR, Li Y, et al. Smart polymeric nanoparticles for pancreatic cancer. Smart Mater Med. 2025;6:368–386.
21. Liu Y, Yang G, Jin S, Xu L, Zhao CX. Development of stimulus-responsive nanocarriers. Adv Drug Deliv Rev. 2020;158:174–194.
22. Cabral H, Kataoka K. Progress of nanomedicine in cancer therapy. J Control Release. 2020;320:493–503.
23. Wang Y, Zhou K, Huang G, Hensley C, Huang X, Ma X, et al. Stimuli-responsive nanocarriers for drug delivery. Adv Mater. 2021;33:e2008457.
24. Zhang Y, Chan HF, Leong KW. Advanced materials for cancer nanomedicine. Adv Drug Deliv Rev. 2020;155:155–176.
25. Yu G, Yu S, Saha ML, Zhou J, Cook TR, Yung BC, et al. Supramolecular nanotheranostics. Nat Commun. 2020;11:5785.
26. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2021;6:1–19.
27. Torchilin VP. Multifunctional nanocarriers. Nat Rev Drug Discov. 2021;20:145–160.
28. He Z, Huang J, Xu Y, Zhang X, Teng Y. pH-responsive nanomedicine. Acta Pharm Sin B. 2021;11:335–349.
29. Wang H, Agarwal P, Zhao S, Yu J, Lu X, He X. Redox-responsive nanocarriers. Adv Mater. 2021;33:e2007212.
30. Chen Q, Liang C, Wang X, He J, Li Y, Liu Z. Stimuli-responsive nanomedicine for cancer. Adv Mater. 2020;32:e1906209.
31. Ding Y, Sun Z, Tong Z, Zhang S, Min J. Enzyme-responsive nanocarriers. Biomaterials. 2020;245:119983.
32. Li Y, Lin TY, Luo Y, Liu Q, Xiao W. Tumor microenvironment targeting. ACS Nano. 2021;15:11920–11930.
33. Huang Y, Fan W, Long Y, Wang C. Magnetic-responsive nanomedicine. Biomaterials. 2022;280:121321.
34. Liu J, Detrembleur C, De Pauw-Gillet MC, Mornet S. Gold nanocarriers. Adv Drug Deliv Rev. 2020;165–166:193–212.
35. Zhang P, Liu G, Chen X. Nanobioengineering in cancer therapy. Chem Soc Rev. 2020;49:311–334.
36. Wu W, Pu Y, Shi J. Nanomedicine-enabled immunotherapy. Nano Today. 2021;38:101149.
37. Dai Y, Xu C, Sun X, Chen X. Nanoparticle design for cancer therapy. Chem Soc Rev. 2020;49:3862–3886.
38. Li X, Yang Y, Huang L. Gene delivery nanocarriers. Nat Rev Mater. 2021;6:829–846.
39. Zhang C, Pu K. Molecular and nanoengineering approaches. Chem Soc Rev. 2020;49:4234–4253.
40. Cheng R, Meng F, Deng C, Klok HA, Zhong Z. Dual-responsive nanocarriers. Biomaterials. 2020;232:119706.
41. Sun Q, Zhou Z, Qiu N, Shen Y. Rational design of cancer nanomedicine. Adv Mater. 2021;33:e2006620.
42. Yu M, Zheng J. Clearance pathways of nanomedicine. ACS Nano. 2021;15:12448–12469.
43. Liu Z, Jiang W, Nam J, Moon JJ, Kim BYS. Immunomodulating nanomedicine. Nat Rev Immunol. 2021;21:25–41.
44. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine. Nat Rev Cancer. 2020;20:20–37.
45. Chen H, Zhang W, Zhu G, Xie J, Chen X. Rethinking cancer nanotheranostics. Nat Rev Mater. 2021;6:451–468.
46. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design. Nat Biotechnol. 2020;38:915–928.
47. Lammers T, Kiessling F, Ashford M, Hennink W, Crommelin D, Storm G. Nanomedicine translation. Nat Rev Mater. 2020;5:643–656.
48. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery. Nat Rev Mater. 2020;5:45–60.
49. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanomedicine. Nat Rev Drug Discov. 2021;20:101–124.
50. Lyu Y, Pu K. Molecularly precise nanomedicine. Adv Mater. 2020;32:e1905331